Table 3.

Clostridioides (Clostridium) difficile Infection Relapse and Reinfection Results at Day 90 (mFAS)

Treatment arm	EPFX	Vancomycin	Total
Patients with CDI recurrence	n = 11	n = 34	n = 45
Patients in mFAS	177	179	356
Tested pairs, n (%)a	7 (15.6)	19 (42.2)	26 (57.8)
Relapse (≤2 SNV)	1 (2.2)	3 (6.7)	4 (8.9)
Reinfection (>10 SNV)	5 (11.1)	15 (33.3)	20 (44.4)
Indeterminate (>2 but ≤10 SNV)	1 (2.2)	1 (2.2)	2 (4.4)
No SNV results available, n (%)	4 (8.9)	15 (33.3)	19 (42.2)

Abbreviations: CDI, C difficile infection; EPFX, extended-pulsed fidaxomicin; mFAS, modified full analysis set (all randomized patients with positive local laboratory test for C difficile toxin A/B at screening who received at least one dose of study medication); SNV, single nucleotide variant.

^aPercentages are calculated over the total number of patients who experienced CDI recurrence in both treatment arms.